Short term pain perhaps but even if the stock does perform the pre-existing shareholders don't share much of it. My issue is the deal.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025